Clinical factors influencing outcome in metastatic colorectal cancer (mCRC) patients treated with fluoropyrimidine and bevacizumab (FP + Bev) maintenance treatment (Tx) vs observation: A pooled analysis of the phase 3 CAIRO3 and AIO 0207 trials

K. Goey; S. Elias; A. Hinke; M. van Oijen; C. Punt; S. Hegewisch Becker; D. Arnold; M. Koopman

doi:https://doi.org/10.1093/annonc/mdw370.12

Clinical factors influencing outcome in metastatic colorectal cancer (mCRC) patients treated with fluoropyrimidine and bevacizumab (FP + Bev) maintenance treatment (Tx) vs observation: A pooled analysis of the phase 3 CAIRO3 and AIO 0207 trials

K. Goey, S. Elias, A. Hinke, M. van Oijen, C. Punt, S. Hegewisch Becker, D. Arnold, M. Koopman

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	vi153
Journal	Annals of Oncology
Volume	27
DOIs	https://doi.org/10.1093/annonc/mdw370.12
Publication status	Published - 2016

Access to Document

https://doi.org/10.1093/annonc/mdw370.12

Cite this

Goey, K., Elias, S., Hinke, A., van Oijen, M., Punt, C., Becker, S. H., Arnold, D., & Koopman, M. (2016). Clinical factors influencing outcome in metastatic colorectal cancer (mCRC) patients treated with fluoropyrimidine and bevacizumab (FP + Bev) maintenance treatment (Tx) vs observation: A pooled analysis of the phase 3 CAIRO3 and AIO 0207 trials. Annals of Oncology, 27, vi153. https://doi.org/10.1093/annonc/mdw370.12

@article{91df821753814b37a77dc3452ba012ef,

title = "Clinical factors influencing outcome in metastatic colorectal cancer (mCRC) patients treated with fluoropyrimidine and bevacizumab (FP + Bev) maintenance treatment (Tx) vs observation: A pooled analysis of the phase 3 CAIRO3 and AIO 0207 trials",

author = "K. Goey and S. Elias and A. Hinke and {van Oijen}, M. and C. Punt and Becker, {S. Hegewisch} and D. Arnold and M. Koopman",

year = "2016",

doi = "https://doi.org/10.1093/annonc/mdw370.12",

language = "English",

volume = "27",

pages = "vi153",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

Goey, K, Elias, S, Hinke, A, van Oijen, M, Punt, C, Becker, SH, Arnold, D & Koopman, M 2016, 'Clinical factors influencing outcome in metastatic colorectal cancer (mCRC) patients treated with fluoropyrimidine and bevacizumab (FP + Bev) maintenance treatment (Tx) vs observation: A pooled analysis of the phase 3 CAIRO3 and AIO 0207 trials', Annals of Oncology, vol. 27, pp. vi153. https://doi.org/10.1093/annonc/mdw370.12

Clinical factors influencing outcome in metastatic colorectal cancer (mCRC) patients treated with fluoropyrimidine and bevacizumab (FP + Bev) maintenance treatment (Tx) vs observation: A pooled analysis of the phase 3 CAIRO3 and AIO 0207 trials. / Goey, K.; Elias, S.; Hinke, A. et al.
In: Annals of Oncology, Vol. 27, 2016, p. vi153.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Clinical factors influencing outcome in metastatic colorectal cancer (mCRC) patients treated with fluoropyrimidine and bevacizumab (FP + Bev) maintenance treatment (Tx) vs observation: A pooled analysis of the phase 3 CAIRO3 and AIO 0207 trials

AU - Goey, K.

AU - Elias, S.

AU - Hinke, A.

AU - van Oijen, M.

AU - Punt, C.

AU - Becker, S. Hegewisch

AU - Arnold, D.

AU - Koopman, M.

PY - 2016

Y1 - 2016

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85083628691&origin=inward

U2 - https://doi.org/10.1093/annonc/mdw370.12

DO - https://doi.org/10.1093/annonc/mdw370.12

M3 - Article

SN - 0923-7534

VL - 27

SP - vi153

JO - Annals of Oncology

JF - Annals of Oncology

ER -

Goey K, Elias S, Hinke A, van Oijen M, Punt C, Becker SH et al. Clinical factors influencing outcome in metastatic colorectal cancer (mCRC) patients treated with fluoropyrimidine and bevacizumab (FP + Bev) maintenance treatment (Tx) vs observation: A pooled analysis of the phase 3 CAIRO3 and AIO 0207 trials. Annals of Oncology. 2016;27:vi153. doi: https://doi.org/10.1093/annonc/mdw370.12

Clinical factors influencing outcome in metastatic colorectal cancer (mCRC) patients treated with fluoropyrimidine and bevacizumab (FP + Bev) maintenance treatment (Tx) vs observation: A pooled analysis of the phase 3 CAIRO3 and AIO 0207 trials

Access to Document

Other files and links

Cite this